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INTRODUCTION
In 1998, David Relman described features of a
number of poorly understood clinical syndromes
that strongly indicate a microbial etiology. His list
of chronic inflammatory diseases with possible
microbial etiologies included sarcoidosis, inflammatory
bowel disease, rheumatoid arthritis, systemic lupus
erythematosus, Wegener granulomatosis, diabetes
mellitus, primary biliary cirrhosis, tropical sprue and
[1]
Kawasaki disease . He noted that molecular methods
of microbial identification offer an alternative when
culture based microbial detection methods fail. His
prediction regarding the emerging importance of
molecular methods has proven correct since the
combination of molecular methods of microbial
detection and improvements in culture methods has
led to advances in the field of paratuberculosis.
Mycobacterium avium subsp. paratuberculosis
(MAP) is a bacterium that causes Johne’s disease, a
[2]
chronic diarrheal wasting disease in cattle and sub[3]
human primates and a chronic wasting disease
[2]
in sheep and goats . In Johne’s disease, it is well
documented that once an animal is infected with MAP,
the MAP bacterium grows and multiplies inside the
macrophages of the immune system. The organism is
[2]
excreted in the feces, and to a lesser extent in milk .
Outside the host animal, MAP multiplies poorly, but
can survive for extended periods in the environment
because of its resistance to heat, cold and the effect
[2]
of drying . This slow-growing bacterium affects
the ileum and causes diarrhea and cachexia. There
are anecdotal reports of Johne’s disease in which
prolonged administration of antibiotics resulted in
[4]
suppression but not cure of the disease .
The viable bacterium has been found in commercially
[5,6]
[6]
available pasteurized milk . Ellingson et al reported
that 2.7% of retail pasteurized milk samples purchased
in Wisconsin, Minnesota and California contained
viable MAP. Because of the presence of this organism
in the food supply, it would not be surprising if MAP
is widespread in the environment and the human
population. The first mass screening study for evidence
of MAP infection in humans was done in North India on
serum, blood and stool samples submitted from patients
with multiple medical conditions including diabetes,
liver disorders, anemia, thyroid, tuberculosis, typhoid,
abdominal disorders, inflammatory illness and ion
[7]
imbalance. Singh et al reported that 34% of 23196
serum samples had anti-MAP antibodies (a comparison
with normal subjects was not included). The same
study showed that 12.7% of 1246 blood samples from
normal healthy individuals had IS900 PCR evidence of
MAP in their blood and 8.4% of 3093 blood samples
from patients with the above listed medical conditions
had PCR evidence of MAP.
It has been suggested for years that there may
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A cohort of family members with various chronic
diseases including Crohn’s disease, asthma, complex
regional pain syndrome, hypothyroidism, type 1
diabetes mellitus, and lymphangiomatosis and/or
evidence of infection by Mycobacterium avium subsp.
paratuberculosis (MAP) are described in this series
of case reports. MAP was cultured from the blood
of three members affected by the first five diseases
and there was accompanying elevated anti-MAP IgG
in two members. The patient affected by the sixth
disease has a markedly elevated anti-MAP titer. The
two patients affected by the first four diseases have
been treated with a combination of anti-MAP antibiotics
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of the disease symptomatology and inability to
culture MAP in post treatment blood samples. These
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supportive evidence of a pathogenic role of MAP in
humans.
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Core tip: Five patients with multiple diseases of unknown
etiology were found to have evidence of infection by
Mycobacterium avium subsp. paratuberculosis (MAP)
including positive blood cultures (except in case 4). Two
of the cases (case 1 with Crohn’s disease and asthma
and case 2 with complex regional pain syndrome,
hypothyroidism and Raynaud’s phenomenon) have been
treated with a combination of anti-MAP antibiotics and
ultraviolet blood irradiation therapy with resolution of
the disease symptomatology and inability to culture MAP
in post treatment blood samples. These case reports of
patients with MAP infections provide supportive evidence
of a pathogenic role of MAP in humans.
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be an association between Crohn’s disease (CD)
and Johne’s disease. Dalziel first speculated in 1913
that chronic enteritis, now known as CD, might be
[8]
caused by MAP and Chiodini first reported the
culturing of mycobacteria from the intestinal tissues
[9]
of CD patients . For many years, the data were
[2,10,11]
conflicting
and the theory that MAP causes CD
[12-14]
remains controversial
. Later on, Hermon-Taylor
and others described a case of a boy with cervical
lymphadenitis caused by MAP who later developed
[15]
CD . Recent studies show an increase in the detection
[16]
and isolation of MAP in adult Crohn’s patients
and
[17]
in children with newly diagnosed CD
Meta-analyses
[18]
[19]
by Feller et al and Abubakar et al have concluded
that a majority of studies on the association of MAP
and CD show that most patients with CD have MAP
[20]
infection. In 2004, Naser et al
reported culturing
MAP from the blood of 50% of patients with CD and
this work was confirmed in four laboratories including
[21,22]
the Centers for Disease Control and Prevention
.
In addition, a large, randomized, double-blind,
placebo-controlled study from Australia showed a
significant but not lasting response of individuals
with CD who were treated with antibiotics against
[23]
MAP
Apparently unaware that antibiotics fail to
cure a majority of patients with Mycobacterium
[24]
avium complex infection (MAC) , the authors
incorrectly concluded that because they failed to cure
patients, CD could not be caused by mycobacterial
infection. This study and the conclusions of its
[25,26]
authors were significantly flawed
. The editorial
which accompanied the article acknowledged
that, “subtherapeutic doses of rifabutin (450 mg),
clarithromycin (750 mg) and clofazimine (50 mg) per
day were used, whereas the optimal dose of rifabutin,
clarithromycin and clofazimine for treatment of M
avium complex infections is 600 mg/d, 1000-2000
[27]
mg/d, and 100 mg/d, respectively” . A recent metaanalysis of antibiotic trials in CD conducted by Feller
and coworkers concludes that a substantial benefit was
evident in trials using nitroimidazoles, clofazimine and
ciprofloxacin and that a combination of clarithromycin
[28]
and rifamycin and ciprofloxacin should be studied .
Most research attention in inflammatory bowel
disease has focused on the genetics of CD rather than
the association of the disease with paratuberculosis
infection. However, these two areas of research
are probably complementary because the genetic
mutations, which have been described, may indicate
increased susceptibility to MAP infection. Also in cattle,
NOD2 mutations are associated with susceptibility to
[29]
MAP infection , and this same mutation has been
linked to patients with CD. A 2009 study from China
showed that patients with another mycobacterial
infection, leprosy, and patients with CD have higher
rates of the NOD2, TNFSF15 and IL12B mutations
[30,31]
than healthy controls
. A large meta-analysis
genome-wide association study concluded that there
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is considerable overlap between the susceptibility loci
[32]
for IBD and mycobacterial infection . In the only
simulated human-challenge trial, Israeli researchers
showed that fetal human small intestine explants in
mice with severe combined immunodeficiency and
then inoculated with MAP intraluminally, showed
invasion of the goblet cells, tissue damage and
[33]
inflammation .
In 2006, Dow postulated that MAP may be the
[34]
trigger for typeⅠdiabetes mellitus (T1DM) because of
the association of T1DM with mutations of the SLC11a1
[35]
gene . This gene encodes a membrane protein of the
lysozymes of monocytes and macrophages. Mutations
in this gene have been associated with susceptibility to
infectious diseases including tuberculosis and leprosy
and lead to a more hospitable host environment for
[36]
bacterial survival and replication . Subsequently,
Sechi and others reported an association of MAP and
[37-39]
[40]
T1DM
. Recently, Naser et al showed that there is
a high degree of homology between GAD65 and Hsp65
which supports a mycobacterial role in the immune
destruction of the beta cells of the pancreatic islets
through molecular mimicry.
Additional findings in T1DM also present in other
mycobacterial infections include elevated angiotensin
[41,42]
converting enzyme (ACE) levels
and elevated
[43]
vascular endothelial growth factor (VEGF) . VEGF
has been reported to be elevated in active pulmonary
tuberculosis and to decline following successful
[44]
treatment . Some 24.5% of patients with T1DM have
a positive Saccharomyces cerevisiae Antibody (ASCA)
test which is similar to the frequency of ASCA positivity
[45]
in Crohn’s disease . Consumption of milk is a risk
[46,47]
factor for the development of T1DM
.
Frau and others have also reported an association
[48]
of MAP and multiple sclerosis (MS) . Consumption of
[49]
milk is also a risk factor for the development of MS .
The following case reports demonstrate an
association of MAP with several of the above described
diseases as well as with two diseases which have not
yet been linked to MAP. In addition, the diseases which
were treated with anti-MAP therapy resolved.

Assays for evidence of MAP infection

Three assays were performed on EDTA blood samples
from each patient (Figure 1). The plasma was assayed
for antibodies to MAP by ELISA using culture filtrate
[50]
antigens of MAP strain UCF-4 as described .
Peripheral blood leukocytes were harvested and
used for DNA extraction followed by IS900 PCR as
[51]
described . The remainder of the leukocytes were
inoculated into BACTEC MGIT ParaTB medium with
supplements but without antibiotics and incubated
for 6 mo at 37 ℃. After incubation, the culture pellets
were harvested and subjected to DNA extraction,
[22]
followed by nested IS900 PCR as described .
Subcultures were done on all PCR-positive MGIT
cultures to attempt recovery of MAP in pure culture.
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EDTA blood
ELISA for antibodies to MAP
DNA extraction
+ IS900 PCR

PBL

MGIT tube + supplements
! no antibiotics!

x 6 mo. @ 37 ℃

DNA extraction:
yield = 50 mL

Harvest 1 mL
From tube bottom
27 mL for re-testing
store in freezer

st

23 mL for 1 PCR

nd

1 mL for 2 PCR

All samples with a positive nested IS900 PCR
Will be sent to a reference lab for sequencing

Figure 1 Schematic of sample processing and testing methods.

antibody solution were added per well and plates were
incubated at room temperature for 30 min. Plates were
washed as before and 100 µL of room temperature
3,3′,5,5′-tetramethylbenzidine were added per well.
Plates were incubated at room temperature for 10 min.
The reaction was stopped by adding 100 µL of 2 mol/L
sulfuric acid per well. Plates were read at 450 nm using
an iMark Microplate Reader (BioRad).

CASE REPORT
Case 1

At the Children’s Hospital of Wisconsin, Dr. Grzegorz
Telega began following a 9-year-old boy who was
diagnosed with CD in June 2004. He initially presented
in 2004 with persistent diarrhea, weight loss and
unexplained fever. His linear growth had slowed
considerably. Colonscopy and upper gastrointestinal
endoscopy showed multiple aphthous ulcers in the
colon, terminal ileum and stomach (Figure 2) and
biopsies obtained in the colon and gastric antrum
contained the granulomas of CD (Figure 3). His
erythrocyte sedimentation rate (ESR) and C reactive
protein (CRP) were increased.
MAP testing was performed on the patient’s blood.
The initial sample showed mildly elevated antibody
titers to one of the MAP antigens, p35, and after
several months of incubation, MAP was grown from the
patient’s blood. The second sample drawn more than
3 mo later showed greater elevations of antibodies to

Figure 2 Terminal ileum with multiple ulcers.

Assay for evidence of leprosy

One assay was performed to detect antibodies to M.
leprae based on phenolic glycolipid-1 antigen. The
assay was performed as described earlier for Para[52]
LP-01 based lipid-ELISA for Johne’s disease . Wells
were coated with 100 ng PGL-1 dissolved in isopropanol and dried. Plates were blocked for one hour
at room temperature with 100 µL 3% BSA (in PBS, pH
[52]
7.4). ELISA was then performed . One hundred µL of
subject serum diluted 1:20 in 10% FBS/PBS (pH 7.4)
was added to the wells and incubated for 30 min at
room temperature. Plates were washed three times with
PBS followed by adding secondary conjugated antibody
(sheep anti-human IgH-h+1 HRP conjugated antibody
diluted 1:2000 in 10% FBS/PBS). 100 µL of secondary
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Table 1 Summary of Mycobacterium avium subsp. paratuberculosis antibody, PCR and culture results for cases 1 through 5

MAP Ab

MAP PCR
MAP culture
MAP Ab

MAP PCR
MAP culture

MAP Ab

MAP PCR
MAP culture
MAP Ab

MAP PCR
MAP culture
MAP Ab

MAP PCR
MAP culture

Case 1

Case 2

Case 3

Case 4

Case 5

5/11/04
p35-0.25
p36-0.16
5/11/04
negative
5/11/04
positive
8/18/04
p35-0.5
p36-0.3
8/18/04
negative
8/18/04
positive
Anti-MAP
therapy
started
8/19/04
9/20/04
p35-0.33
p36-0.22
9/20/04
negative
9/20/04
positive
7/9/07
negative

11/6/12
ELISA S/P
1.24
11/6/12
negative
11/6/12
negative
11/20/12
ELISA S/P
1.31
11/20/12
negative
11/20/12
positive
Anti-MAP
therapy
started
12/15/12
4/17/13
ELISA S/P
1.20
4/17/13
negative
4/17/13
negative
5/7/14
ELISA S/P
1.69
5/7/14
negative
5/7/14
negative

1/14/13
ELISA S/P
0.49
1/14/13
negative
1/14/13
negative

3/14/13
ELISA S/P
1.72
3/14/13
negative
3/14/13
negative
Month/yearpending

1/10/13
ELISA S/P
0.15
1/10/13
negative
1/10/13
positive

7/9/07
negative
7/9/07
negative
5/27/14
ELISA S/P
0.67
5/27/14
negative
5/27/14
negative

1/18/13
positive

Month/yearpending
Month/yearpending

MAP: Mycobacterium avium subsp. Paratuberculosis.

pain and frequency of diarrhea. At the time of the initial
diagnosis, the patient was 4 feet 8.75 inches or in the
th
th
95 percentile in stature and weighed 71.8 pounds (75
percentile). Prior to the onset of illness, his weight
th
had previously reached 80 pounds (90 percentile).
Initially, in August 2004, the patient received
azathioprine and steroids with concurrent antibiotic
therapy including clarithromycin and rifabutin, in low
[23]
doses similar to those used in the Australian trial .
Dr. Telega, the pediatric gastroenterologist, prescribed
the antibiotics and received consultative advice initially
from Dr. Hermon-Taylor and later additionally from
Drs. Chamberlin and Borody. The patient also took
daily probiotics, which were administered at mid-day.
After 7 d of antibiotic therapy, as predicted by Dr. John
Hermon-Taylor the patient developed a mild fever that
lasted for several days, which Dr. Hermon-Taylor had
previously observed in other patients and compared to
a Jarish Herxheimer reaction. Because of an elevated
ALT and AST, the azathioprine was discontinued in

100 mm

Figure 3 Biopsy from the colon showing a granuloma of Crohn’s disease.

both p35 and p36 antigens and also grew MAP (See
Table 1 for the summary of MAP testing in this and
the subsequent 4 cases). During the 3 mo between
the initial and second sample, the patient’s clinical
condition steadily worsened with increasing abdominal

WJG|www.wjgnet.com
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Legend:
Tuberculosis
Diabetes mellitus type 1
Hypothyroidism
Hyperthyroidism
Asthma
Crohn’s disease
Lymphangiomatosis
Complex regional pain syndrome
Rheumatoid arthritis
Chronic lymphocytic leukemia
002

003

004
Case 5

001

012 013
Case 3

011

010

009

008

014

015

016

005 007 006
Case 2
Case 1

Case 4

Figure 4 Family pedigree summarizing history of mycobacterial infection and other diseases of cases 1 through 5 and additional family members.

December 2004. The patient responded favorably to
the antibiotics for about 8 mo, but by June 2005, he
became symptomatic and relapsed (a finding similar to
that of the Australian trial). The period of relapse lasted
from June 2005 to March 2006 and during this time
he remained on low dose antibiotics. A colonoscopy on
January 11, 2006 showed multiple aphthous ulcers in
the colon and his weight on that day was 77.3 pounds
th
(35 kg). On January 13 a short course of prednisone
th
was initiated at a dose of 10 mg/d. On January 15 ,
the dose of prednisone was increased to 20 mg/d. By
th
February 11 , his weight was 90 pounds (41 kg).
In late 2005, in addition to receiving antibiotics,
over the course of a three-month period, the patient
received a total of 11 once weekly ultraviolet blood
irradiation (UVBI) treatments which were performed
by Dr. Mitchell Kurk at his office in Long Island, New
York. A similar UVBI device has been successfully
advanced through phase Ⅱ clinical trials at the FDA.
In addition to UVBI therapy, on advice from
experts, the doses of clarithromycin and rifabutin were
increased and ciprofloxacin was added to the regimen.
On January 13, 2006, the patient was started on
ciprofloxacin at a dose of 125 mg taken twice per day
(7 mg/kg per day) and two weeks later this dose was
increased to 250 mg taken twice per day (14 mg/kg
per day). On February 12, 2006, when the patient
weighed 90 pounds (41 kg) the dose of clarithromycin
was increased to 750 mg, 500 mg taken in the am
and 250 mg taken in the pm (18 mg/kg per day) and
the dose of rifabutin was increased to 450 mg taken
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150 mg in the am and 300 mg in the pm (11 mg/kg
per day). In May 2006, after the patient was in clinical
remission, clofazimine (an antibiotic with restricted use
in the United States which is used for the treatment
of leprosy and Mycobacterium avium complex) was
added at a dose of 50 mg taken once daily. The
clofazimine was obtained from a source in Australia.
The patient had a history of seasonal (triggered by
pollen) asthma beginning at age 3 years and the last
episode of asthma he has experienced was in April
2006.
These antibiotics have been used in many prior
studies to treat MAP in humans. The doses in this
patient were adjusted over time. He received over 4
years of continuous antibiotic therapy until January
2009. From January 2009, he was on cycled therapy
of rifabutin, ciprofloxacin and clarithromycin until May
2011. The patient has been in complete remission
since April 2006.
Since May 2011, he has received no medications
of any type and he has been without any signs or
symptoms of CD and is now 5 feet 10.5 inches and 185
pounds (84.1 kg). A follow-up blood culture for MAP
in July 2007 failed to recover MAP by culture or detect
MAP DNA by PCR and he tested negative for anti- MAP
antibody. Currently, he has a normal blood count and
is negative for inflammatory markers including ESR
and CRP. A colonoscopy and upper gastrointestinal
endoscopy in August, 2014 were normal. There are
many reports in the literature of patients with CD who
[28,53-55]
have responded favorably to antibiotic therapy
.
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Case 2

lymphocytosis and November 20, 2012 when her
antibody titer increased to 1.31 and the organism could
now be cultured while she no longer had monocytosis
and lymphocytosis. During this two week period she
developed generalized extreme hypersensitivity to
minor tactile stimuli. MAP experts were consulted and
appropriate antibiotics were prescribed.
Other diagnostic test results included elevated
cryoglobulins of 57 (normal 0-50 ug/mL) and ACE
[57-59]
level of 59 (normal 8-53 U/L). Cryoglobulins
and
[60,61]
ACE
are elevated in other mycobacterial infections
including tuberculosis and leprosy. Prior to the onset
of disease and the initiation of therapy, the patient
had persistent relative lymphocytosis and eosinophilia
which was present as early as 1997. Relative lym
[62]
phocytosis has been described in tuberculosis .
[63]
Neurologic findings are not uncommon in CD . In
addition, siblings of patients with CD are at much higher
[64]
risk of developing CD than the general population .
In mid December 2012, the patient was placed on
anti-MAP therapy and supplementary Vitamin A and
Vitamin D similar to that administered to her brother.
Her height and weight are 5 feet 9.5 inches and 150
pounds (68.2 kg), respectively and her antibiotic doses
were as follows: Clarithromycin 500 mg twice daily
(15 mg/kg per day), rifampin 300 mg twice daily (9
mg/kg per day), levofloxacin 500 mg per day (7 mg/
kg per day) and clofazimine 100 mg 3 times per week
(4 mg/kg per week). Four days after the initiation of
therapy she experienced a mild fever which lasted two
days. Dr. Stuart Weg performed 12 UVBI treatments
at weekly intervals for 3 mo from January through
early April 2013. Previously, Weg speculated that CRPS
is due to an infection caused by a cell wall deficient
[65]
bacterium .
Dr. David Haas of the University of Charleston
Chemistry Department, confirmed by gas chro
matography, mass spectroscopy, ultraviolet absorption
spectroscopy and infrared spectroscopy that the
clofazimine, which was imported from India, was not a
counterfeit drug.
Following the initiation of therapy, she developed
monocytosis and the relative lymphocytosis persisted.
Since that time, she has shown marked clinical im
provement including disappearance of the generalized
hypersensitivity, disappearance of the previously
grossly visible Raynaud’s phenomenon in her hands,
and improved ability to perform motor skills with a
reduction in reported pain. By the fall of 2014, she could
swim one mile or walk five miles per day. Although
her general condition has greatly improved including
absence of the generalized extreme hypersensitivity,
she still experiences episodes of migratory pain. With
treatment of leprosy, reversal reactions and prolonged
[66]
neuralgia have been observed .
Six weeks after beginning the anti-MAP therapy,
while still taking supplemental thyroxine, she began
experiencing palpitations and it was noted that her
TSH had dropped to the low normal range. On the

In early 2012, the sibling of case 1, a 23-year-old
female began experiencing symptoms initially thought
to be carpal tunnel syndrome and by August 2012,
developed Raynaud’s phenomenon in both hands.
She had a several year history of hypothyroidism and
was on thyroid hormone replacement. The symptoms
of neuralgia and paresthesia progressively advanced
and involved her bilateral hands, elbows, shoulders,
neck, legs and feet. By the time she was seen at the
Cleveland Clinic Neurological Center for Pain in late
November, the physician who examined her noted
Raynaud’s phenomenon in both hands and described
the purple color change and cold temperature as
profound.
Her workup included a normal EMG study,
normal CT scan of the brain, and normal values for
procalcitonin, ESR, CRP, IL-6, ASCA IgA and IgG,
rheumatoid factor, ANA, SS-A/RO, SS-B/LA, SCL, RNP,
SM, CCP, JO-1, Centromere antibodies, Anti-Hu TTGIgA, lyme serology, gliadin peptide IgA and IgG, antiendomysial IgA, serum MPA IgG, MPA IgA, MPA IgM,
MPA kappa, MPA lambda, MPA kappa/lambda ratio,
glutamic acid decarboxylase antibody and ganglioside
antibody studies. Because of a history of travel to
Guatamala 5 years prior to the onset of her illness, the
patient’s blood was tested for antibody to M. leprae.
The PGL-1 assay was negative. The initial diagnosis
at the Cleveland Clinic was hypersensitivity syndrome
and the patient was referred to the Cleveland Clinic
Neurological Center for Pain where she received the
diagnosis of thoracic outlet syndrome with probable
evolving complex regional pain syndrome (CRPS).
Recommendations for therapy included physical
therapy, muscle relaxants and gabapentin. Gabapentin
at the lowest recommended dose made her very dizzy
and therefore, she discontinued this medication. The
patient obtained multiple sessions of physical therapy
which were beneficial and engaged in gradually
increasing regular exercise including walking and
swimming as tolerated. In December 2012, she could
only walk 300 feet or tread water wearing a floatation
device for 5 min. The cause of this condition is
unknown.
Due to suspicion that CRPS could be a manifestation
of a MAP infection, blood samples were tested for
evidence of MAP infection; the first blood sample
was obtained November 6, 2012 and the second on
November 20, 2012. The results of the MAP ELISA
assays from both samples showed significantly
elevated titers, S/P values of 1.24 and 1.31
respectively, where the positive control serum was
from a veterinarian who had accidentally injected
himself with the MAP vaccine. The MAP PCR tests were
both negative. MAP was detected by culture from the
second blood sample. There was rapid progression
of clinical disease between November 6, 2012 when
her MAP antibody titer was 1.24 and the organism
could not be cultured while she had monocytosis and
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presumption that the palpitations indicated that her
thyroid function was recovering, in January 2013, she
stopped supplemental thyroxine, has not experienced
symptoms of hypothyroidism, and her TSH is now in
the normal range. A TSH from May 7, 2014 was 4.06
µIU/mL (reference range 0.350-5.55 µIU/mL). An ACE
level from May 7, 2014 was still elevated at 58 U/L
and a complete blood count from the same day was
normal except for mild monocytosis of 9.3 % (reference
range 0%-8%) and eosinophilia of 9.5% (reference
range 0%-4%). By October 14, 2014, a complete
blood count and differential were normal.
After four months of therapy (April 7, 2013), a
follow-up blood culture for MAP showed a minimally
decreased MAP ELISA S/P value of 1.2, the MAP PCR
test was negative and MAP could not be cultured from
this sample. A follow-up cryoglobulin study obtained
from April 17, 2013 was negative after 4 h and
positive after 72 h. In early January 2014, the patient
consulted Dr. Kuruvilla John who has since that time
followed her case.

ointment containing azelaic acid. In 2004, his blood
was found positive for antibodies to p35 and p36 MAP
antigens.
Because of the devastating nature of the diseases
in case 1 and case 2 and the poor record of efficacy,
standard therapies were eschewed. Institutional
review board (IRB) approval was not sought since the
law allows off label use of FDA approved drugs and
also allows the administration of UVBI in New York.
IRB approval is generally not required in the care of
individual patients. In cases 1 through 3, infectious
disease specialists were consulted and informed about
the elevated MAP ELISA antibody titers and/or positive
MAP cultures but declined to make recommendations
regarding therapy.
Additional family members were tested for evidence
of MAP infection as well. The mother of case 1 and
case 2 was negative for MAP by PCR on PBMC and
culture, and had an ELISA S/P of 0.08 (negative).
The brother of case 1 and case 2 had a negative
MAP PCR and negative culture and ELISA S/P of 0.59
(slightly elevated). The maternal grandfather of case
1 and case 2 had a negative MAP PCR on PBMCs and
negative culture and an ELISA S/P of 0.13 (negative).
The maternal grandmother (with hypothyroidism) of
case 1 and case 2 had a negative MAP PCR on PBMCs
and negative MAP culture and an ELISA S/P of 0.0
(negative).
The families of both parents of case 1 and case
2 have a history of susceptibility to mycobacterial
infection. Figure 4 which is a family pedigree sum
marizing the cases and the mycobacterial infection and
other disease history in other members.

Case 3

Since two siblings had evidence of MAP infections
and responded to anti-MAP therapy, other relatives
were tested. The paternal uncle of cases 1 and 2, who
has longstanding T1DM, is also infected with MAP. In
addition, the uncle was found to have elevated ASCA
IgA, a serologic marker, which is present in T1DM and
[45]
CD . The uncle’s MAP serum antibody S/P value was
0.49 (negative). The patient has declined treatment
for MAP.

Case 4

The nephew of the mother of cases 1 and 2 has
lymphangiomatosis, a disease of unknown etiology.
His blood showed a MAP ELISA antibody S/P value
of 1.72 (exceptionally high). His MAP PCR and MAP
culture results were negative. He had a very elevated
VEGF of 506 pg/mL (reference range of 31-86 pg/
mL), mild monocytosis of 992 (reference range of
200-950 cells/uL) and a normal neopterin test, ASCA
IgA and IgG, and ACE tests. The MAP ELISA study,
VEGF and monocytosis in this case suggest a possible
mycobacterial causation of lymphangiomatosis and
further study is indicated.

DISCUSSION
The presence of viable MAP in the blood of a majority
of CD patients is an important finding which has been
[20,22]
previously reported by Naser
. Some observers
ascribe this phenomenon to the “leaky bowel” resulting
[67]
from mucosal disruption in CD . In case 1, the
recovery of the viable organism in the setting of two
diseases and the failure to recover the viable organism
in the absence of these two diseases argues in favor of
a pathogenic role of MAP in these patients. Similarly,
in case 2, the recovery of the viable organism in the
setting of two other diseases and the failure to recover
the organism in the absence of these two other
diseases also argues in favor of a pathogenic role of
MAP. Furthermore, the recovery of the viable organism
in case 2 in which the patient suffered from CRPS
cannot be explained by the leaky bowel hypothesis
since this patient has not experienced bowel related
symptoms. In addition, a pathogenic role of MAP in the
human host is likely, considering the zoonotic capacity
of slow-growing mycobacteria and because this
organism is an obligate pathogen, i.e., one which does
[68]
not propagate in the environment .

Case 5

The father of cases 1 and 2 was tested for MAP
infection. After 6 mo of incubation, MAP was grown
from his blood. His MAP PCR on PBMCs was negative
and his MAP ELISA antibody S/P value was 0.15
(negative). He is healthy but suffered from seasonal
asthma (triggered by pollen) at age 12 years and
also while living in Germany from 1986 to 1989. In
addition, he has rosacea, which was diagnosed by
clinical signs and a skin biopsy showing non-caseating
granulomas. This condition is treated with a topical
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[74]

A second possible interpretation of the findings in
these case reports is that the diseases were not caused
by MAP and went into remission spontaneously. In the
consideration of the probable events in case 1 and case
2, the percentage of patients who experience long term
remissions in CD, CRPS, hypothyroidism and Raynaud’s
[69]
[70]
[71]
[72]
phenomenon is 10% , 74% , 62% , and 64% ,
respectively. With the assumption that case 1 and
case 2 resolved spontaneously, the outcome follows
the likelihood function. The probability of spontaneous
resolution in case 1 is 0.10 and in case 2 is 0.30 (0.74 ×
0.62 × 0.64 = 0.30) and the probability of spontaneous
resolution in both patients is 0.10 × 0.30 or 0.03 which
is very unlikely. Controlled clinical trials of anti-MAP
therapy are necessary to determine whether these
case reports are reproducible. Clinical trials have been
designed and funding is being sought.
A third possible interpretation of the recovery of
MAP from the blood samples in case 1 and in case
2, is that the MAP organism is a contaminant from
specimen processing. This interpretation is unlikely
since in both cases there are increased antibodies
directed against MAP indicating a host response to the
organism. The presence of elevated serologic markers
which are associated with mycobacterial infection,
including CRP in case 1 and ACE in case 2, also weighs
against this possibility.
We believe that the profound long lasting remission
in case 1 resulted from anti-MAP therapy and is unlikely
due to steroid administration, since such remissions
rarely result from steroid administration alone. Based
on these anecdotal reports, three additional cases of
children with CD and MAP infection treated successfully
with combination anti-MAP antibiotics and UVBI
(personal communication), open label trials in CD,
and controlled trials in MAC infection, we recommend
the use of three antibiotics including clarithromycin,
rifampin and levofloxacin (at 15, 9 and 7, respectively,
mg/kg per day) for at least two years in combination
with periodic UVBI (if available). However, at this time,
the optimal antibiotic combination is unknown.
In cases 1 and 2, the rapid progression of the
disease accompanied by an increase in antibodies to
MAP antigens between the first two specimens may
mirror Johne’s disease in dairy cattle in which the
progression in the severity of disease and the degree
of mycobacterial colonization coincides with a switch
[73]
from the TH1 to TH2 type immune response .
The presence of the viable bacterium in the blood
of an apparently healthy host (case 5) is an interesting
finding. Apparently healthy individuals may have less
virulent forms of disease such as transient childhood
asthma or rosacea as noted in case 5. In addition, if
MAP-infected people are followed over a long enough
period of time, some may eventually develop one of
the diseases traditionally considered autoimmune.
It would not be surprising if there is a population
of individuals who are MAP-infected but never develop
disease. Mycobacterium tuberculosis, causes active
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disease in only 10% of infected humans . A similar
situation probably pertains to human paratuberculosis,
i.e., most MAP infected individuals may never develop
disease. Clinically normal cattle with known MAP
infection are common suggesting a parallel in the
[75]
human population .
Any theory of causation of the autoimmune
diseases must explain two consistent observations for
most of these diseases: (1) the north south gradient
in geographical distribution of the disease (in the
[76]
northern hemisphere) ; and (2) the predominant
female to male ratio in most of these diseases. The
first observation is concordant with the worldwide
[77]
distribution of Johne’s disease , the lower levels of
[78]
Vitamin D in the human host at northern latitudes ,
and the role of Vitamin D in the clinical course of
[79,80]
patients with CD and T1DM
. A possible explanation
for the second observation includes reduced host
immunity due to the effects of estradiol and/or
[81-83]
progesterone
. Future work may shed light on the
immunology of gender differences with these diseases.
Because of the known risk of disease progression in
CD from birth control medication, women who have
been diagnosed and treated for a MAP infection should
consider non-hormonal birth control methods.
The optimal hosts for MAP are ruminants; cattle,
sheep, and deer, in which, a higher burden of bacteria
are generally found than in humans. These animals
have a higher body temperature than humans ranging
from 100.4 to 102.8, 100.9 to 103.8 to 104 F, for cattle,
[84,85]
sheep and deer, respectively
. These differences in
body temperature suggests that the growth of MAP in
laboratory culture may be accelerated by raising the
incubation temperature to 104 F. Further investigation
of this issue is warranted.
If controlled trials of MAP related illnesses confirm
the findings of these case reports and the autoimmune
diseases can be cured, because the bacterium is
present in the food supply, will treated patients
redevelop disease on re-exposure to the organism?
The precautionary principle should apply and improved
food safety and public health measures are necessary
to limit human exposure to MAP. Until improved
measures are in place, treated and cured patients
should probably avoid known sources of MAP which
include pasteurized milk and milk products such as
yoghurt, cheese and ice cream and undercooked beef.
Open label trials of long-term antibiotic therapy in
CD have a significant relapse rate. Adjunctive therapy
such as UVBI combined with appropriate antibiotics
may be a way to improve therapeutic outcomes.
[86]
UVBI was developed by Knott . In his article on the
development of ultraviolet blood irradiation, he refers
to the work of European investigators who “believed
that most of the systemic reactions observed following
exposure of the skin to ultraviolet rays were due to
[86]
the influence of the rays upon the blood” . Knott
was most likely aware of the work of Finsen who
received the Nobel Prize in 1903, for his work showing
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the beneficial effects of ultraviolet treatments of the
skin in patients with lupus vulgaris, i.e., tuberculosis
[87]
of the skin . The Knott device was used for the
[88-90]
treatment of many infections
. and while exact
figures are unavailable, probably thousands of patients
were treated with this therapy throughout the United
[91,92]
States. Several studies
as well as three controlled
trials from Russia have shown beneficial effects in
[93-95]
the treatment of tuberculosis
. Because the Knott
hemo-irradiator predated the advent of the FDA, this
device was never FDA approved. However, in recent
years, UVBI was advanced successfully through
phase Ⅱ clinical trials for the treatment of hepatitis C
infection.
Various studies on UVBI that may explain the
benefit of this therapy include the following. Ultraviolet
light in the C region (UVC) inactivates bacterial
and viral pathogens, present in the blood, which is
irradiated. In the case of bacteria and DNA viruses,
UVC induces the formation of thymine-thymine
[96]
dimers, which prevents replication . In the case of
RNA viruses, UVC induces the formation of uracil-uracil
[97]
dimers which also prevents replication . Bacteria
including Mycobacterium tuberculosis have UV repair
mechanisms and normal lymphocytes also have UV
[98,99]
repair mechanisms
.
Because only 200 cc of blood in an average adult
(or 4% of the total 5.0 liter blood volume) is treated
during a single session, factors other than pathogen
inactivation are likely to explain the potential benefit.
Ultraviolet light shined on murine fibroblasts results
in the formation of hydrogen peroxide and hydroxyl
[100]
radicals which are also bactericidal and virucidal
.
Ultraviolet light in the A region and at higher doses
and exposure durations causes immune suppression,
but ultraviolet light in the B (UVB) region and UVC
[101-103]
have been shown to stimulate dendritic cells
.
Hemoglobin which has been irradiated with UVB and
[104]
UVC wavelengths exhibits fluorescence
and the
wavelength of light which is emitted, 365 nm, causes
the formation of DNA or RNA adducts in riboflavin and
other chromophores and these adducts are bactericidal
[105]
and virucidal . It is now known that in spite of long
term treatment of tuberculosis by antibiotics, there
[106,107]
are persisters, which are not killed by the drugs
.
Also Mycobacterium avium complex organisms can
resist the bactericidal activity of clarithromycin within
[108]
the phagosomes of macrophages
. Viable MAP
organisms which have survived the antibiotics by either
of these routes and which are within macrophages
[68]
may not survive ultraviolet irradiation . An in-vitro
study showed that monocytes which are irradiated
with UVB and then infected with Mycobacterium avium
intracellulare (MAI) organisms, efficiently inhibit the
[109]
intracellular replication of MAI . The authors in this
work speculated that the intracellular inhibition of MAI
replication in the UV treated macrophages may be due
to the induction of intracellular vitamin D production by
the UVB.
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Vitamin D has been shown to play an important
role in the host immune response to mycobacterial
[110]
infection
. Vitamins A and D have been shown to
[111]
inhibit the growth of MAP in vitro
. Vitamin D has
also been shown to reduce the proliferation of M.
[112]
tuberculosis in macrophages
. Activated dendritic
[113]
cells are known to produce Vitamin D
and Vitamin
D induces the intracellular production of cathelicidin,
[114]
which is an antimicrobial protein
. High levels of
Vitamin D have been correlated with a reduced risk of
developing multiple sclerosis, and Vitamin D intake is
inversely associated with rheumatoid arthritis (another
autoimmune condition) and the severity of this latter
[113]
disease also correlates with Vitamin D levels .
Finally, many types of cells including leukocytes and,
in particular, monocytes, exposed to ultraviolet light
secrete heat shock proteins and these proteins play an
[115-117]
important role in the response to infection
.
A small open label trial of UVBI in 4 patients with
severe Raynaud’s syndrome showed clinical improvement
that lasted for 3 mo in all of the patients and a reduction
of mycobacterial heat shock protein antibodies in one of
[118]
the patients .
These case reports support a pathogenic role of
MAP in humans. Large controlled trials are indicated
for many of the autoimmune diseases associated
with MAP infection including CD, T1DM, MS and CRPS
using anti-MAP therapy combined with UVBI (perhaps
[119]
substituting ethambutol for ciprofloxacin)
in one
arm and combination infliximab and azathioprine in
the control arm to determine whether properly dosed
anti-MAP therapy is more effective than currently
available therapies. RedHill Biopharma Ltd., Tel Aviv,
Israel, has initiated phase Ⅲ clinical trials in Europe
and North America to treat CD and MS using a
combination therapy of clarithromycin, rifabutin and
[120]
clofazimine . MAP prevalence studies are indicated in
lymphangiomatosis, ankylosing spondylitis, rheumatoid
arthritis, hypothyroidism, hyperthyroidism, adrenal
insufficiency, systemic sclerosis, Sjogren syndrome,
systemic lupus erythematosus, dermatomyositis,
psoriasis, sarcoidosis, celiac disease, rosacea, asthma,
fibromyalgia, amyotrophic lateral sclerosis, myasthenia
gravis, Parkinson’s disease and Alzheimer’s disease.
The results of therapeutic trials should be evaluated
with consideration of the success rate in treating
Mycobacterium avium complex infections, a mere
[27]
42%
and that the treatment of Mycobacterium
leprae is associated with an absolute relapse rate of 3%
and that relapses may occur more than 10 years after
[121]
multiple drug therapy has concluded .
Researchers who explore the role of MAP in the
autoimmune diseases should be aware that our
current diagnostic tests are crude. The ELISA for
46
serum antibodies to MAP was adapted from the
cattle assay which has a sensitivity of only 30% to
[122]
40% in cattle which are known to be MAP-infected .
The suboptimal sensitivity and the variation between
current serologic assays for MAP make the diagnosis
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allergy while the differential diagnosis in case 2 included multiple sclerosis.

of MAP infection difficult. However, in the presence
of otherwise unexplained autoimmune disease, the
occurrence of positive blood cultures for MAP should be
a significant finding.
Furthermore, pre-existing therapies for these
conditions may hinder culture recovery methods.
Many of the currently used immunomodulators
have demonstrated bacteriostatic effects on MAP in[123,124]
vitro
. When possible, MAP diagnostic testing
should be conducted on newly diagnosed patients prior
to instituting immunosuppressive therapies which can
inhibit the growth of MAP in cultures. While the blood
culture method of Naser has been a great advance
in the field of human paratuberculosis research, it is
positive in 55% of patients with inflammatory bowel
disease and in 22% of non-inflammatory bowel
[22]
disease patients , and therefore cannot by itself
serve as a discriminator for the presence or absence
of disease. Concurrent detection of antibodies directed
[50]
at MAP will probably be helpful in this regard . MAP
cultures should be performed in laboratories with
[125]
expertise. Parrish et al
failed to replicate the blood
culture study of Naser et al, but their method did not
include egg yolk in the medium (regarded by many as
vital for MAP growth) and the cultures were only held
for 18 wk (MAP cultures for humans are usually held
for at least 6 mo and up to one year).
The current MAP ELISA reacts to both host IgM and
IgG. Modifying the assay into its isotype components,
i.e., IgM and IgG, may permit a better determination
of whether the host response reflects active disease or
remote exposure. Further research is necessary in this
area.
Should MAP be proven to cause many of the auto
immune diseases, a potential role in carcinogenesis
should be explored. Helicobacter pylori is now recognized
as playing a major role in the pathogenesis of primary
[126]
gastric MALT lymphoma and gastric carcinoma . CD
patients are known to have increased risk of bowel
cancer and lymphoma. Whether this increased risk is
due to the immunosuppressive therapies used in this
disease or due to infection by MAP is unknown and
[127]
should be investigated further . In summary, much
more must be learned about this elusive and enigmatic
organism and about the human diseases with which it is
associated.

Laboratory diagnosis

Please summarize laboratory testing methods and major findings in one
sentence. Case 1 had anemia, elevated erythrocyte sedimentation rate,
CRP and WBC while case 2 had elevated angiotensin converting enzyme,
cryoglobulins, lymphocyte and eosinophil count and TSH and initially,
both patients had blood cultures positive for Mycobacterium avium subsp.
paratuberculosis (MAP).

Imaging diagnosis

Please summarize imaging methods and major findings in one sentence. Case
1 had multiple aphthous ulcers on upper gastrointestinal endoscopy and on
colonoscopy while case 2 had an unremarkable EMG study.

Pathological diagnosis

Please summarize pathological methods and major findings in one sentence.
Case 1 had granulomas in the gastric and colonic biopsies while case 2 had no
biopsies.

Treatment

Please summarize treatments and drugs used in one sentence. Both case 1
and case 2 received a combination of periodic ultraviolet blood irradiation (UVBI)
and antibiotics which included clarithromycin, rifampin and ciprofloxacin for at
least 2 years.

Related reports

Please provide other contents related to the case report to help readers better
understand the present case.

Term explanation

Please explain uncommon terms present in the case report. UVBI is ultraviolet
blood irradiation which consists of periodic irradiation of approximately 200 cc
of patient blood using ultraviolet light in the B and C regions.

Experiences and lessons

Please summarize experiences and lessons learnt from the case in one
sentence. Both CD and CRPS, when caused by MAP, resolve when the
organism is eradicated from the host.

Peer-review

Please summarize the strengths and weaknesses of the article based on the
reviewers’ comments so that readers can obtain objective knowledge from the
article. This study is anecdotal and it will be necessary to study large numbers
of patients in a controlled trial setting to determine whether these results are
reproducible.
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